Molecular Basis for Synaptotagmin-1-Associated Neurodevelopmental Disorder

Neuron. 2020 Jul 8;107(1):52-64.e7. doi: 10.1016/j.neuron.2020.04.003. Epub 2020 May 1.

Abstract

At neuronal synapses, synaptotagmin-1 (syt1) acts as a Ca2+ sensor that synchronizes neurotransmitter release with Ca2+ influx during action potential firing. Heterozygous missense mutations in syt1 have recently been associated with a severe but heterogeneous developmental syndrome, termed syt1-associated neurodevelopmental disorder. Well-defined pathogenic mechanisms, and the basis for phenotypic heterogeneity in this disorder, remain unknown. Here, we report the clinical, physiological, and biophysical characterization of three syt1 mutations from human patients. Synaptic transmission was impaired in neurons expressing mutant variants, which demonstrated potent, graded dominant-negative effects. Biophysical interrogation of the mutant variants revealed novel mechanistic features concerning the cooperative action, and functional specialization, of the tandem Ca2+-sensing domains of syt1. These mechanistic studies led to the discovery that a clinically approved K+ channel antagonist is able to rescue the dominant-negative heterozygous phenotype. Our results establish a molecular cause, basis for phenotypic heterogeneity, and potential treatment approach for syt1-associated neurodevelopmental disorder.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Animals
  • Cells, Cultured
  • Humans
  • Mice
  • Neurodevelopmental Disorders / genetics*
  • Neurodevelopmental Disorders / physiopathology
  • Neurons / drug effects
  • Neurons / physiology*
  • Potassium Channel Blockers / pharmacology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / genetics*
  • Synaptotagmin I / chemistry
  • Synaptotagmin I / genetics*

Substances

  • Potassium Channel Blockers
  • SYT1 protein, human
  • Synaptotagmin I
  • 4-Aminopyridine